Document is current

Article History

Received: 13 November 2024

Accepted: 23 January 2025

First Online: 8 February 2025

Declarations

:

: Antonio Martorell, Pierre-André Becherel, John R. Ingram, Barry M. McGrath, and Marco Romanelli have received honoraria for their participation in the global HS Implementation Science working group. John R. Ingram has acted as a consultant and/or advisory board member for Abbvie, Novartis, UCB Pharma, ChemoCentryx, Boehringer Ingelheim, Insmed, Viela Bio, MoonLake, Union Therapeutics, and Kymera Therapeutics; he also received an editorial stipend from the British Journal of Dermatology as Editor-in-Chief and an author honorarium from UpToDate and is co-copyright holder of HiSQoL and Investigator and Patient Global Assessment instruments for HS. John R. Ingram’s department received royalties from the DLQI and related instruments. Georgios Kokolakis is or has acted as a speaker and/or advisory board member for honoraria from AbbVie, Abbott, Actelion Pharmaceuticals, Amgen, Basilea Pharmaceutica, Bayer, Biogen IDEC, Boehringer, Bristol-Myers Squibb, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Lilly, MSD, Mylan, Novartis, Parexel, Pfizer, Sanofi, Sharpe and Dohme, Takeda and UCB Pharma. Barry M. McGrath has received disease-related consultancy/advisory board honoraria from Incyte, Novartis and UCB Pharma. Marco Romanelli has received financial support for lectures, consultations and/or research studies from the following companies: AbbVie, Almirall, Bristol Myers Squib, ConvaTec, Eli Lilly, Janssen Cilag, KLOX Technologies, Novartis, Paul Hartmann, Sanofi Genzyme and Urgo. Falk G. Bechara has received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Acelyrin, Beiersdorf, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Incyte Corporation, JanssenCilag GmbH, Johnson & Johnson, Merck, Mölnlycke, MoonLake, Novartis Pharma GmbH, Sanofi, Sitala, UCB Pharma and Dr. Wolff. Antonio Martorell has received honoraria and/or travel grants and/or has acted as an advisory board member for Novartis, AbbVie, Janssen Cilag, UCB Pharma, Lilly, LEO Pharma, L’Oreal, Sanofi, Boehringer Ingelheim, Almirall, Bristol Myers Squib and Amgen. He has also worked as a principal investigator in clinical trials supported by AbbVie, UCB Pharma, Jansen, Bristol Myers Squibb, Lilly, Galderma, Sanofi, and Novartis. Mona Biermann, Yvonne Geissbühler, Benjamin M. Haeberle, Mahrukh Zahid, Michael Fritz are stakeholders and/or employees of Novartis Pharma AG. Erhard Quebe-Fehling was an employee of Novartis Pharma AG at the time of study development and is now retired, currently a Statistical Consultant at Cogitars GmbH. Craig Richardson was an employee of Novartis Pharma AG at the time of study development and is now retired. Pierre-André Becherel has received consulting fees from Novartis, AbbVie, Pfizer, and UCB Pharma; payment or honoraria from Novartis and AbbVie; support for attending meetings or travel from Novartis; and served on a Data Safety Monitoring Board or Advisory Board for Novartis.

: Ethics committee approval was not required in Germany for this study, as only anonymized data from patients are collected.